Retatrutide is a next-generation triple agonist targeting GLP-1, GIP, and glucagon receptors. Clinical trials have shown weight-loss magnitudes exceeding Tirzepatide — making it a leading option for clients who have plateaued on existing GLP-1 therapy or face refractory metabolic dysfunction. Available through research-guided protocols.
Best for: Clients who have plateaued on other GLP-1 therapies, refractory metabolic dysfunction.
Every TAI peptide protocol is lab-guided and provider-led. Start with biomarkers, design around your goals, refine at intervals. Available in-clinic and via telehealth.